A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pruritus is often refractory to treatment with existing therapies. This phase 2 study assessed the efficacy and safety of maralixibat, a selective, ileal, apical, sodium‐dependent, bile acid transporter inhibitor, in adults with PBC and pruritus. Adults with PBC and pruritus who had received ursodeoxycholic acid (UDCA) for ≥6 months or were intolerant to UDCA were randomized 2:1 to maralixibat (10 or 20 mg/day) or placebo for 13 weeks in combination with UDCA (when tolerated). The primary outcome was change in Adult Itch Reported Outcome (ItchRO™) average weekly sum score (0, no itching; 70, maximum itching) from baseline to week 13/early termination (ET). The study enrolled 66 patients (maralixibat [both doses combined], n = 42; placebo, n = 24). Mean ItchRO™ weekly sum scores decreased from baseline to week 13/ET with maralixibat (–26.5; 95% confidence interval [CI], –31.8, –21.2) and placebo (–23.4; 95% CI, –30.3, –16.4). The difference between groups was not significant (P = 0.48). In the maralixibat and placebo groups, adverse events (AEs) were reported in 97.6% and 70.8% of patients, respectively. Gastrointestinal disorders were the most frequently reported AEs (maralixibat, 78.6%; placebo, 50.0%). Conclusion: Reductions in pruritus did not differ significantly between maralixibat and placebo. However, a large placebo effect may have confounded assessment of pruritus. Lessons learned from this rigorously designed and executed trial are indispensable for understanding how to approach trials assessing pruritus as the primary endpoint and the therapeutic window of bile acid uptake inhibition as a therapeutic strategy in PBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Lysophosphatidic Acid Is a Potential Mediator of Cholestatic Pruritus
Kremer, A. E., Martens, J. J. W. W., Kulik, W., Ruëff, F., Kuiper, E. M. M., van Buuren, H. R., van Erpecum, K. J., Kondrackiene, J., Prieto, J., Rust, C., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.009 · Cited by 410
Hegade, V. S., Kendrick, S. F. W., Dobbins, R. L., Miller, S. R., Thompson, D., Richards, D., Storey, J., Dukes, G. E., Corrigan, M., Oude Elferink, R. P. J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30319-7 · Cited by 206
Self-citationJones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis
Datta, D. V., & Sherlock, S. (1966) · Gastroenterology · doi:10.1016/s0016-5085(66)80071-9 · Cited by 181 · cited 1×
“(17) Reduced pruritus has been observed in patients with cholestatic liver disease following partial external biliary diversion surgery or administration of bile acid sequestrants, which also interrupt enterohepatic circulation of bile acids.(18-20) Use of a pharmacologic agent, such as maralixibat, to block reabsorpt…”
BackgroundTandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · cited 1×
“The magnitude of this improvement from baseline (maralixibat overall, 52%; placebo, 47%), based on the means at baseline and week13/ET in ItchROTM weekly sum scores, was similar to that reported in trials of medications recommended in practice guidelines for cholestatic pruritus, such as naltrexone and rifampin.(7,28)…”
ResultQuality of life in patients with primary biliary cirrhosis
Poupon, R. E., Chrétien, Y., Chazouillères, O., Poupon, R., & Chwalow, J. (2004) · Hepatology · doi:10.1002/hep.20276 · Cited by 144 · cited 1×
“366 and can significantly impair patients’ quality of life.(3) In particular, severe pruritus impairs sleep quality.”
BackgroundBergasa, N. V., McGee, M., Ginsburg, I. H., & Engler, D. (2006) · Hepatology · doi:10.1002/hep.21370 · Cited by 107
Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’
Beuers, U., Gershwin, M. E., Gish, R. G., Invernizzi, P., Jones, D. E. J., Lindor, K., Ma, X., Mackay, I. R., Parés, A., Tanaka, A., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.031 · Cited by 97
Self-citation
Cited by
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Self-citationLleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Self-citationLevy, C., Kendrick, S., Bowlus, C. L., Tanaka, A., Jones, D., Kremer, A. E., Mayo, M. J., Haque, N., von Maltzahn, R., Allinder, M., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.032 · Cited by 101
Self-citationClinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
“Recently, an animal study using humanized anti-CD20 antibody on an unique murine model human CD20 and human Fcγ receptors in the dnTGFβRII mice model of PBC effectively attenuated PBC liver pathηlogy and liver infiltration of CD8+ Tcells, Table 2 Current experimental therapies and clinical trials in PBC Mechanisms Cli…”
BackgroundSelf-citation
Metadata
- Authors
- Mayo, M. J., Pockros, P. J., Jones, D., Bowlus, C. L., Levy, C., Patanwala, I., Bacon, B., Luketic, V., Vuppalanchi, R., Medendorp, S., Dorenbaum, A., Kennedy, C., Novak, P., Gu, J., Apostol, G., & Hirschfield, G. M.
- Venue
- Hepatology Communications
- Published
- 2019-02-01
- Volume
- 3
- Issue
- 3
- Pages
- 365-381
- ISSN
- 2471-254X (ISSN-L)
- OpenAlex
- W2915023124
- Cited by
- 97
- References
- 11
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.